{"id":"NCT04269707","sponsor":"American Regent, Inc.","briefTitle":"Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients With Iron Deficiency Anemia and Unsatisfactory Response Oral Iron Under Study Protocol 1VIT17044","officialTitle":"Evaluating the Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients With Iron Deficiency Anemia and an Unsatisfactory Response to Oral Iron Under Study Protocol 1VIT17044","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-11-19","primaryCompletion":"2020-12-30","completion":"2021-01-29","firstPosted":"2020-02-17","resultsPosted":"2022-03-21","lastUpdate":"2022-03-21"},"enrollment":7,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Iron Deficiency Anemia"],"interventions":[{"type":"DRUG","name":"Ferric carboxymaltose","otherNames":[]}],"arms":[{"label":"IV Iron","type":"OTHER"}],"summary":"Evaluating the Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients with Iron Deficiency Anemia and an Unsatisfactory Response to Oral Iron under Study Protocol 1VIT17044","primaryOutcome":{"measure":"Change in Hemoglobin From Baseline to Day 35","timeFrame":"The change in Hgb from baseline to day 35","effectByArm":[{"arm":"IV Iron","deltaMin":0.7,"sd":null}],"pValues":[{"comp":"OG000","p":"0.1711"}]},"eligibility":{"minAge":"1 Year","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":2,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":7},"commonTop":[]}}